Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver

Andrew Kennedy*, Douglas Coldwell, Bruno Sangro, Harpreet Wasan, Riad Salem

*Corresponding author for this work

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Surgical resection of hepatic metastases from neuroendocrine tumors (mNETs) is controversial because the potential survival benefit of this intervention must be balanced against the risk of surgical morbidity and mortality. In patients with unresectable mNETs in the liver, radioembolization has been used to treat tumors from a range of primary sites, including carcinoid and islet cell carcinomas as well as nonfunctional, asymptomatic tumors. Initial clinical studies and retrospective studies on a large cohort of patients indicate that radioembolization is well tolerated and highly effective in achieving a durable hepatic tumor response and ameliorating symptoms. Radioembolization using Yttrium-90 ( 90Y)-labeled resin or glass microspheres offers effective disease control and possible improved quality of life and thus merits consideration as an option for both functional and nonfunctional mNETs. Benefits of this intervention seem to extend from use in early lines of treatment to salvage of refractory disease. Radioembolization also offers a potential somatostatin analog-sparing effect in symptomatic disease.

Original languageEnglish (US)
Pages (from-to)393-398
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume35
Issue number4
DOIs
StatePublished - Aug 1 2012

Fingerprint

Neuroendocrine Tumors
Neoplasm Metastasis
Liver
Islet Cell Carcinoma
Yttrium
Salvage Therapy
Neoplasms
Carcinoid Tumor
Somatostatin
Microspheres
Glass
Therapeutics
Retrospective Studies
Quality of Life
Morbidity
Survival
Mortality

Keywords

  • SIRT
  • Yttrium-90
  • carcinoid
  • hepatic
  • metastases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{71995f6712cf48a0a3a9e568824935ca,
title = "Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver",
abstract = "Surgical resection of hepatic metastases from neuroendocrine tumors (mNETs) is controversial because the potential survival benefit of this intervention must be balanced against the risk of surgical morbidity and mortality. In patients with unresectable mNETs in the liver, radioembolization has been used to treat tumors from a range of primary sites, including carcinoid and islet cell carcinomas as well as nonfunctional, asymptomatic tumors. Initial clinical studies and retrospective studies on a large cohort of patients indicate that radioembolization is well tolerated and highly effective in achieving a durable hepatic tumor response and ameliorating symptoms. Radioembolization using Yttrium-90 ( 90Y)-labeled resin or glass microspheres offers effective disease control and possible improved quality of life and thus merits consideration as an option for both functional and nonfunctional mNETs. Benefits of this intervention seem to extend from use in early lines of treatment to salvage of refractory disease. Radioembolization also offers a potential somatostatin analog-sparing effect in symptomatic disease.",
keywords = "SIRT, Yttrium-90, carcinoid, hepatic, metastases",
author = "Andrew Kennedy and Douglas Coldwell and Bruno Sangro and Harpreet Wasan and Riad Salem",
year = "2012",
month = "8",
day = "1",
doi = "10.1097/COC.0b013e3182005768",
language = "English (US)",
volume = "35",
pages = "393--398",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. / Kennedy, Andrew; Coldwell, Douglas; Sangro, Bruno; Wasan, Harpreet; Salem, Riad.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 35, No. 4, 01.08.2012, p. 393-398.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver

AU - Kennedy, Andrew

AU - Coldwell, Douglas

AU - Sangro, Bruno

AU - Wasan, Harpreet

AU - Salem, Riad

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Surgical resection of hepatic metastases from neuroendocrine tumors (mNETs) is controversial because the potential survival benefit of this intervention must be balanced against the risk of surgical morbidity and mortality. In patients with unresectable mNETs in the liver, radioembolization has been used to treat tumors from a range of primary sites, including carcinoid and islet cell carcinomas as well as nonfunctional, asymptomatic tumors. Initial clinical studies and retrospective studies on a large cohort of patients indicate that radioembolization is well tolerated and highly effective in achieving a durable hepatic tumor response and ameliorating symptoms. Radioembolization using Yttrium-90 ( 90Y)-labeled resin or glass microspheres offers effective disease control and possible improved quality of life and thus merits consideration as an option for both functional and nonfunctional mNETs. Benefits of this intervention seem to extend from use in early lines of treatment to salvage of refractory disease. Radioembolization also offers a potential somatostatin analog-sparing effect in symptomatic disease.

AB - Surgical resection of hepatic metastases from neuroendocrine tumors (mNETs) is controversial because the potential survival benefit of this intervention must be balanced against the risk of surgical morbidity and mortality. In patients with unresectable mNETs in the liver, radioembolization has been used to treat tumors from a range of primary sites, including carcinoid and islet cell carcinomas as well as nonfunctional, asymptomatic tumors. Initial clinical studies and retrospective studies on a large cohort of patients indicate that radioembolization is well tolerated and highly effective in achieving a durable hepatic tumor response and ameliorating symptoms. Radioembolization using Yttrium-90 ( 90Y)-labeled resin or glass microspheres offers effective disease control and possible improved quality of life and thus merits consideration as an option for both functional and nonfunctional mNETs. Benefits of this intervention seem to extend from use in early lines of treatment to salvage of refractory disease. Radioembolization also offers a potential somatostatin analog-sparing effect in symptomatic disease.

KW - SIRT

KW - Yttrium-90

KW - carcinoid

KW - hepatic

KW - metastases

UR - http://www.scopus.com/inward/record.url?scp=84864368497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864368497&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3182005768

DO - 10.1097/COC.0b013e3182005768

M3 - Review article

C2 - 21278561

AN - SCOPUS:84864368497

VL - 35

SP - 393

EP - 398

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -